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To replicate, HIV-1 capitalizes on endogenous cellular activation pathways resulting in recruitment of key host
transcription factors to its viral enhancer. RNA interference has been a powerful tool for blocking key checkpoints in
HIV-1 entry into cells. Here we apply RNA interference to HIV-1 transcription in primary macrophages, a major reservoir
of the virus, and specifically target the transcription factor NFAT5 (nuclear factor of activated T cells 5), which is the
most evolutionarily divergent NFAT protein. By molecularly cloning and sequencing isolates from multiple viral
subtypes, and performing DNase I footprinting, electrophoretic mobility shift, and promoter mutagenesis transfection
assays, we demonstrate that NFAT5 functionally interacts with a specific enhancer binding site conserved in HIV-1, HIV-
2, and multiple simian immunodeficiency viruses. Using small interfering RNA to ablate expression of endogenous
NFAT5 protein, we show that the replication of three major HIV-1 viral subtypes (B, C, and E) is dependent upon NFAT5
in human primary differentiated macrophages. Our results define a novel host factor–viral enhancer interaction that
reveals a new regulatory role for NFAT5 and defines a functional DNA motif conserved across HIV-1 subtypes and
representative simian immunodeficiency viruses. Inhibition of the NFAT5–LTR interaction may thus present a novel
therapeutic target to suppress HIV-1 replication and progression of AIDS.
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Introduction
The monocyte/macrophage lineage and dendritic cells are
the ﬁrst cells to be infected by HIV-1 [1–3] (reviewed in [4–7]).
Monocytes/macrophages are relatively resistant to the cyto-
pathic effects of HIV-1 and thus can serve as a reservoir for
persistent HIV-1 infection [3] (reviewed in [7–10]). Further-
more, based on experiments with HIV-1 subtype B, the ﬁrst
HIV-1 subtype identiﬁed [11], it has been suggested that
signal transduction pathways and transcription factors acting
to modulate HIV-1 gene expression through the HIV-1 long
terminal repeat (LTR) enhancer region are distinct in the
monocyte/macrophage lineage and dendritic cells as com-
pared with T cells [7,12].
A critical step in the replication of HIV-1 is the tran-
scription of viral genes following integration of viral DNA
into the genome of the host cell (reviewed in [13]). However,
the majority of HIV-1 gene transcription studies have been
performed using isolates of subtype B, although multiple
HIV-1 subtypes have a major role in the global HIV-1
pandemic, and each subtype has a distinct sequence of
transcription factor binding sites in its LTR [14–18]. Differ-
ences in the number and arrangement of these activator
binding sites inﬂuence subtype-speciﬁc expression of the
virus in vitro [14,19–21]. The ubiquitous transcription factor
nuclear factor jB (NF-jB) has long been implicated in HIV-1
viral gene transcription in multiple cell types [22,23]
(reviewed in [12,24,25]). Although the NF-jB motifs within
the core jB enhancer/basal promoter of the HIV-1 subtype B
LTR are canonical binding sites for the NF-jB p50/p65
heterodimer [22], they are also recognized by the calcineurin-
dependent proteins of the nuclear factor of activated T cells
(NFAT) family [26–32], which shares a structurally conserved
DNA-binding motif with the NF-jB proteins, the rel
homology region (reviewed in [33–35]).
Nuclear translocation of the two NFAT proteins that have
been shown to play a role in HIV-1 gene transcription and
replication in T cells, NFATp (also known as NFAT1 or
NFATc2), and NFATc (also known as NFAT2 or NFATc1) [26–
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dependent phosphatase calcineurin, as is the case for NFAT3
(also known as NFATc4) and NFAT4 (also known as NFATc3)
(reviewed in [33,34,38]). The most recently identiﬁed NFAT
protein, NFAT5 (also known as TonEBP) [39], is the most
evolutionarily divergent member of the NFAT family: NFAT5
has a homolog in Drosophila, while NFATp, NFATc, NFAT3,
and NFAT4 are found exclusively in vertebrates [40]. NFAT5
was classiﬁed as an NFAT protein on the basis of its rel
homology region domain, since it has greater sequence
similarity with the NFAT protein family than with NF-jB
proteins [39], but it is a unique member in many important
respects. Speciﬁcally, (i) unlike the other NFAT proteins,
NFAT5 binds DNA as an obligate dimer in a fashion similar
to the NF-jB proteins; (ii) NFAT5 does not cooperate with
the basic region leucine zipper proteins Fos and Jun in gene
activation; and (iii) NFAT5 functions independently of
calcinuerin [39,41] (reviewed in [33–35]). Finally, NFAT5
activity is regulated by osmotic stress and integrin activation
[41–43], although the details of the upstream effects of these
and other signal transduction pathways upon NFAT5 remain
to be elucidated.
Here, we have identiﬁed a role for NFAT5 in the
replication of HIV-1 in cells of the monocyte/macrophage
lineage. We show that terminally differentiated macrophages
have high constitutive levels of NFAT5 mRNA and protein,
and that NFAT5 speciﬁcally and functionally binds to a site
conserved in the LTR of HIV-1 subtypes B, C, and E.
Strikingly, this unique NFAT5 site is conserved in all major
HIV-1 subtypes, in HIV-2, and in simian immunodeﬁciency
virus (SIV) from multiple primate species. By targeting
NFAT5 expression with small interfering RNA (siRNA), we
inhibit production of HIV-1 subtypes B, C, and E in human
monocyte-derived macrophages (MDMs). Our results thus
establish a pivotal role of NFAT5 in HIV-1 replication in a
physiological monocyte/macrophage model system of infec-
tion. By demonstrating that HIV-1 replication can be
inhibited in terminally differentiated macrophages by
targeting the transcription factor NFAT5 through RNA
interference, we illustrate a novel approach that may be




HeLa-CD4 [44] cells were obtained from the United States
National Institutes of Health AIDS Research and Reference
Reagent Program (http://www.aidsreagent.org) and were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
(Gibco, http://www.invitrogen.com) supplemented with 10%
FCS, 50 U/ml penicillin, 50 lg/ml streptomycin, 2 mM L-
glutamine, and 500 lg/ml G418. One day before exper-
imental manipulation, cells were washed and incubated in
medium without antibiotics and plated at ;70% conﬂuence.
THP-1 cells were obtained from the AIDS Research and
Reference Reagent Program and were maintained in RPMI
1640 medium (Gibco) supplemented with 10% FCS, 50 U/ml
penicillin, 50 lg /ml streptomycin, and 2 mM L-glutamine.
Transfection of THP-1 cells was performed as described
previously [45], and luciferase assays were performed
according to the manufacturer’s instructions (Dual Lucifer-
ase Reporter Assay System; Promega, http://www.promega.
com) using a Dynex luminometer (http://www.dynextechno-
logies.com), with Renilla luciferase (pRL-TK) as an internal
control.
Preparation of Human MDMs
Human monocytes were isolated from buffy coats prepared
from healthy volunteer donors. Peripheral blood mononu-
clear cells isolated by Ficoll-Hypaque (Pharmacia Corpora-
tion, http://www.pﬁzer.com) density gradient centrifugation
were seeded at 6 3 10
6/2 ml in 12-well plates in RPMI 1640
medium and supplemented with 10% heat-inactivated
human AB serum (Nabi Biopharmaceuticals, http://www.na-
bi.com), 50 U/ml penicillin, 50 lg /ml streptomycin, and 2 mM
L-glutamine. The cell cultures were incubated at 37 8C and
5% CO2 overnight, after which nonadherent cells were
removed by repeated gentle washing with warm medium.
The cells were further incubated for 4 d in fresh medium
before manipulation. More than 95% of the adherent cells
obtained with this technique were CD14þ macrophages.
siRNA Target Sequences and Transfection of Cell Lines
and MDMs
siRNAs were constructed (Ambion, http://www.ambion.
com) to target sequences of NFAT5: NFAT5#1, 59-CAA-
CATGCCTGGAATTCAA-39 (nucleotides [nt] 335 to 353), and
NFAT5#2, 59-CCAGTTCCTACAATGATAA-39 (nt 3981 to
3999). As a control for nonspeciﬁc siRNA effects, we used
siRNA targeting the green ﬂuorescent protein (GFP), 59-
GGCTACGTCCAGGAGCGCACC-39. HeLa-CD4 cells (1 3
10
4) were transfected in 24-well plates with cationic lipid
complexes, prepared by incubating 200 nM of the indicated
siRNA in 3 ll siPORT NeoFX transfection reagent (Ambion),
prepared as recommended by the manufacturer, in a ﬁnal
volume of 500 ll DMEM containing 10% FCS. After 24 h of
incubation, cells were washed and resuspended in fresh
medium. MDMs were seeded in 12-well plates and were
transfected with 1 lM siRNA in 4 ll of siPORT NeoFX
transfection reagent (Ambion), prepared as recommended by
the manufacturer, and added to the cells in a ﬁnal volume of
750 ll RPMI containing 10% human serum. The cultures
were incubated overnight and then washed and incubated in
fresh medium.
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Synopsis
To replicate, viruses exploit the cellular machinery of infected cells in
their hosts. Macrophages, blood cells involved in the body’s defense
against pathogens, are resistant to the toxic effects of certain
viruses, such as HIV-1, the AIDS virus. The drawback, however, is that
macrophages become an avenue through which viruses can spread
to other tissues and organs of the body. Here, Ranjbar, Tsytsykova,
and colleagues have identified a new role for a human protein,
nuclear factor of activated T cells 5 (NFAT5), as a host factor
important for replication of HIV-1 in macrophages. The binding site
for NFAT5 on a region of the HIV-1 DNA critical for its replication, the
long terminal repeat, is the same across multiple subtypes of HIV-1
and the related virus HIV-2, and even the simian immunodeficiency
virus; thus, disrupting the interaction between NFAT5 and the long
terminal repeat provides a potential means of inhibiting replication
of multiple versions of HIV.Viruses
HIV-1Bal and HIV-193TH64 were obtained from the AIDS
Research and Reference Reagent Program. HIV-1LAI and
HIV-198IN22 were obtained from the Centralised Facility for
AIDS Reagents (http://www.nibsc.ac.uk/spotlight/aids.html),
United Kingdom National Institute for Biological Standards
and Control. High titer of virus stock was prepared by
infection of a pool of phytohemagglutinin (Sigma, http://www.
sigmaaldrich.com) and IL-2-stimulated (AIDS Research and
Reference Reagent Program) normal donor peripheral blood
mononuclear cells with each virus for approximately 2 wk.
Supernatants were aliquoted and stored at  70 8C.
HIV-1 Infection
HeLa-CD4 cells were infected with 100 TCID50 of HIV-1LAI
in 1 ml of medium. The cells were incubated overnight, after
which they were washed and 1 ml fresh medium was added to
each culture. After viral challenge, the cells were analyzed for
p24 expression by ﬂow cytometry and real-time PCR. Cell-
free viral production was measured in supernatants using the
HIV-1 p24 ELISA (enzyme-linked immunosorbent assay) kit
(Perkin Elmer, http://las.perkinelmer.com). MDMs were in-
fected with 50 TCID50 of HIV-1Bal, or 100 TCID50 of HIV-
198IN22 or HIV-193TH64 in 1 ml of medium. The cells were
incubated for 24 h, after which they were washed and fresh
medium was added. Supernatants were collected at different
intervals and kept frozen at  70 8C for further analysis.
Flow Cytometry
Uninfected cells or cells infected with HIV-1 were washed
with HBSS, and ﬁxed and permeabilized using the Fix and
Perm kit from Caltag Laboratories (http://www.invitrogen.
com).Thecellswerestainedwithp24-RD1conjugate(Beckman
Coulter, http://www.beckmancoulter.com). Intracellular
NFAT5 levels were determined using NFAT5 antibody (Onco-
gene Research Products, http://www.emdbiosciences.com/g.
asp?f¼CBC/home.html) labeled with phycoerythrin and ana-
lyzed by ﬂow cytometry on a FACSCalibur instrument with
CellQuest software (Becton Dickinson, http://www.
bdbiosciences.com) according to standard techniques [46].
Quantitative PCR
NFAT5 and HIV-1 expression level was determined by real-
time PCR using SYBR green (Applied Biosystems, http://www.
appliedbiosystems.com). The reaction conditions were 95 8C
for 10 min to activate the DNA polymers followed by 40
cycles of 95 8C for 20 s and 60.5 8C for 1 min. The results were
normalized using b-actin as an internal control.
LTR Molecular Clone Construction
LTR molecular clones were constructed by inserting  208
toþ64 nt relative to the transcriptional initiation site of HIV-
1LAI, HIV-1BAL (B subtype), HIV-198IN22, HIV-198CH01 (C
subtype), HIV-193TH64, and HIV-1KR25 (E subtype) into the
pGL3 vector (Promega, http://www.promega.com) using Xho I
and Hind III restriction enzyme sites. Sequences were aligned
and analyzed by using ClustalW (http://www.ebi.ac.uk/
clustalw). The HIV-1LAI NFAT5 mutant (N5-Mut) was created
by using standard PCR-based mutagenesis methods [47].
DNase I Footprinting and Electrophoretic Mobility Shift
Assay
DNase I footprinting of HIV-1 LTR fragments was
performed using recombinant NF-jB (p50/p65), NFATp
(generous gifts from D. Thanos), and NFAT5 (a generous gift
from A. Rao). Brieﬂy, the  208 to þ64–nt fragment of HIV-1
LTRs from subtypes B (HIV-1LAI), C (HIV-198IN22), and E
(HIV-193TH64) were end-labeled with
[ 32 P]ATP using T4
polynucleotide kinase and incubated with increasing
amounts of recombinant proteins. After 30 min of incuba-
tion, the samples were digested with 0.3 units of DNase I for
exactly 1 min, resolved on an 8% denaturing polyacrylamide
gel, and exposed overnight on ﬁlm. In the electrophoretic
mobility shift assay (EMSA) experiment with recombinant
proteins, we used the NF-jB, NFATp, and NFAT5 recombi-
nant proteins described above with oligonucleotides end-
labeled with
[ 32 P]ATP as described [48]. For the EMSA with
nuclear extracts from unstimulated THP-1 cells (Figure S1),
the wild-type LTR oligonucleotide was used along with a
speciﬁc anti-NFAT5 antibody (anti-NFAT5; Santa Cruz
Biotechnology, http://www.scbt.com) or a control antibody
(anti-Ig control, Santa Cruz Biotechnology).
Statistical Analysis
Where applicable, results are expressed as a mean þSEM,
and comparison between two groups was performed using
the unpaired Student’s t-test with the aid of Microsoft Excel
software. p , 0.05 was considered signiﬁcant.
Results
Isolation and Sequence Analysis of Representative HIV-1
Subtype B, C, and E LTRs
To examine the regulation of HIV-1 subtypes by NFAT
proteins, we ﬁrst cloned and sequenced the LTR region ( 208
to þ64 nt) of representative primary HIV-1 C (HIV-198IN22,
India and HIV-1CH01, China) and E (HIV-1KR25, Cambodia)
Figure 1. Alignment of LTR Promoter and Enhancer Sequences in Representative Isolates of Subtypes B, C, and E
Sequence variation within the NF-jb/NFATp, SP1, and TATA box regions that distinguish the C and E subtypes from the B subtype are indicated in the
boxes. Sequences were aligned and analyzed by using ClustalW (http://www.ebi.ac.uk/clustalw).
doi:10.1371/journal.ppat.0020130.g001
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NFAT5: An HIV-1 Host Factor in MonocytesFigure 2. NFAT5 Binds Distinctly to a Motif Conserved in HIV-1 Subtype B, C, and E LTR Promoter Regions
(A) NF-jb, NFATp, and NFAT5 bind to distinct and overlapping sequences in the HIV-1 LTR enhancer/promoter region of HIV-1 subtypes B, C, and E.
Quantitative DNase I footprinting analysis is shown using HIV-1 LTR fragments ( 208 toþ64 nt relative to the transcription start site) from representative
subtype B, C, and E viral isolates and increasing concentrations of recombinant NF-jB (p50/p65), NFATp (20 ng, 100 ng, 400 ng, and 20 lg), or NFAT5
(10 lg, 50 lg, 200 lg, and 1 mg) as shown. The low DNA-binding affinity of NFAT5 relative to NFATp has been noted previously [60]. The regions that
are protected from DNase cleavage by the binding of NF-jB, NFATp, and NFAT5 are indicated with bars. We note that in the case of NFAT5, distinct
cleavage patterns (including a hypersensitive site 59 to the region of DNase I protection) are evident at 200 lg.
(B) Summary of DNase footprinting results with NF-jb, NFATp, and NFAT5, and alignment of HIV-1 LTR nucleotide sequences from representative
isolates from subtypes B, C, and E. The diagram illustrates the sequences protected from DNase cleavage by the binding of NF-jb (blue), NFATp (green),
and NFAT5 (red). The NF-jb, NFATp, and NFAT5 binding sites are boxed. The broken boxes indicate sites that have sequence similarity to NF-jb, NFATp,
and NFAT5 sites, but which do not bind the proteins in the footprinting assay displayed in (A). The GGA repeats in the NFATp core dimer binding region
are shown in bold.
doi:10.1371/journal.ppat.0020130.g002
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NFAT5: An HIV-1 Host Factor in Monocytesand HIV-193TH64 (Thailand)) isolates. We analyzed at least ten
clones from each isolate, determined the dominant sequen-
ces, and compared these results with LTR sequences that we
cloned from the lab-adapted B subtype strains HIV-1BAL and
HIV-1LAI (Figure 1). Strikingly, we found an NFAT5 con-
sensus binding motif (59-RNRNNTTTCCA-39) [39] that was
completely conserved in all of the HIV-1 isolates examined. It
overlaps the NF-jB site proximal to the start site of
transcription in the subtype B isolates, the single NF-jB site
in the subtype E isolates, and the central NF-jB site in the
subtype C isolates (Figure 1). We note that these NFAT5
binding motifs also coincide with NFATp/NFATc binding
sites previously detected in the LTRs of the HIV-1 B, C, and E
subtypes [17,27,30].
NFAT5 Binds to a Conserved Element within the LTRs of
HIV-1 Subtypes B, C, and E
To establish the pattern of NFAT5 binding to B, C, and E
LTRs, we next compared the binding of recombinant NF-jB
p50/p65, NFATp, and NFAT5 proteins to the LTRs ( 208 to
þ64 nt relative to the transcription start site) from HIV-1
subtypes B (HIV-1LAI), C (HIV-1CH01 and HIV-198IN22), and E
(HIV-193TH64), using quantitative DNase I footprinting
analysis.
We detected binding of p50/p65 at the two consensus sites
in the B subtype LTR and the single consensus site in the E
subtype; furthermore, p50/p65 bound to these sites with
similar afﬁnities (Figure 2A, panels 1 and 3; also see summary
in Figure 2B). Interestingly, although the C subtype has three
putative NF-jB binding motifs and the B subtype has two,
approximately the same number of nucleotides is protected
from DNase cleavage using the C and B LTRs, since binding
of p50/p65 does not extend to the 39 jB site in the subtype C
LTR (Figure 2B). The lack of binding of p50/p65 to the 39 site
in the C subtypes can be ascribed to the presence of a
thymine or cytosine in place of the purine that is typically in
the fourth position of most NF-jB binding motifs (reviewed
in [49,50]). We note that a cytosine has been observed in the
fourth position of putative NF-jB motifs in other C isolates
[17,29].
Consistent with previous reports [17,29,51], NFATp binds
to sequences that overlap the NF-jB sites of the three
subtypes (Figure 2A and 2B). In contrast to our results with
p50/p65, the number of nucleotides protected by NFATp in
each of the isolates is approximately the same, although
NFATp exhibits the lowest relative afﬁnity for the E subtype.
This can be explained by further inspection of the LTR
sequences (Figure 2B). The B and C subtypes contain two
identical copies of NF-jB sites (both jB sites in B and the 59
and central jB sites in C); previous studies based on the B
subtype LTR sequence have shown that NFATp binds as a
dimer to this site [28,52]. These sites are 9-bp (base pair)
inverted repeats of GGA core motifs (bold black font in
Figure 2B), a consensus sequence that preferentially binds the
NFATp dimer (J. Falvo, C. Lin, A. Tsytsykova, P. Hwang, D.
Thanos, et al., unpublished data); this pattern does not appear
in the 39 NF-jB-like site in the C subtype, which fails to bind
NFATp or NF-jB p50/p65. The E subtype LTR has one copy
of the conserved NF-jB site and an 8-bp inverted repeat of
the GGA core motif (see dotted line boxed sequences and
green font in Figure 2B), which is not optimal spacing for
NFATp dimer binding (J. Falvo, C. Lin, A. Tsytsykova, P.
Hwang, D. Thanos, et al., unpublished data).
We next investigated whether NFAT5 could bind to the
three LTRs, given that they contain a consensus NFAT5
binding site, 59-RNRNNTTTCCA-39 [39], overlapping the NF-
jB/NFATp dimer binding site proximal to the transcription
start site (Figure 2A, panels 7–9). We found that NFAT5
Figure 3. The NFAT5 Binding Motif Is Conserved in HIV-1, HIV-2, and SIV LTRs
Sequence analysis of HIV-1 Group M subtypes A through G and HIV-1 Group O as well as HIV-2 and selected SIV LTR enhancer/promoter regions.
Numbering is based on B subtype (HIV-1LAI) sequences. The conserved NFAT5 binding motif is highlighted in yellow; the sequence corresponding to
the canonical NF-jB site is in red, and the unique 39 terminal adenine is in blue. Sequences were obtained from the Los Alamos HIV Sequence Database
(http://hiv-web.lanl.gov/content/hiv-db/mainpage.html) [17,56] and aligned using HIV-1 subtype B sequences spanning 123 to 68 nt relative to the
viral transcription start site as a reference.
doi:10.1371/journal.ppat.0020130.g003
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NFAT5: An HIV-1 Host Factor in Monocytesprotected an approximately equal number of nucleotides in
each LTR (Figure 2B), footprinting at the B isolate LTR
(Figure 2A, panel 7) more weakly than the C and E isolates
(Figure 2A, panels 8 and 9). NFAT5 selectively binds the 39
NF-jB/NFATp motif (59-GGGACTTTCCA-39, conserved in all
subtypes examined) instead of the immediately upstream NF-
jB/NFATp motif (59-GGGACTTTCCG-39), which varies by
only a single base pair (underlined). Thus, NFAT5, unlike p50/
p65, discriminates between the tandem NF-jB motifs of the B
and C subtype LTRs (Figure 2B).
These results thus deﬁne the binding site selectivity for NF-
jB p50/p65, NFATp, and NFAT5 at the LTRs of representa-
tives of three different HIV-1 subtypes. Different activators
are able to bind in overlapping, yet distinct patterns within
these enhancer regions, similar to inducer- and cell type–
speciﬁc recruitment of different activators to the tumor
necrosis factor promoter [47,53–55]. In the case of the HIV-1
LTR in three major viral subtypes, a single nucleotide
difference, an adenine immediately 39 of the NF-jB sites,
confers selective binding of NFAT5.
The NFAT5 Binding Site Is Highly Conserved in HIV-1, HIV-
2, and SIV LTRs
We next examined the Los Alamos HIV Sequence Database
(http://hiv-web.lanl.gov/content/hiv-db/mainpage.html) for
LTRs from representatives of HIV-1 Group M (for main)
subtypes A through G, HIV-1 Group O, HIV-2, and ﬁve SIV
LTRs [17,56], including SIVCPZ, the closest relative to HIV-1
[57], to determine whether the NFAT5 binding site we had
discovered was present in other viral subtypes and in SIVs.
Remarkably, we found complete conservation of the NFAT5
binding motif, including the 39 adenine that confers selective
NFAT5 binding over closely related NF-jB sites, in each of
these LTRs (Figure 3).
Specific Disruption of NFAT5 Binding Impairs LTR
Activation
We next examined the functional impact of NFAT5
binding upon LTR-mediated activation of transcription.
Inspection of the NF-jB/NFATp/NFAT5 shared binding
element suggested that we could disrupt NFAT5 but not
NF-jB binding by mutating two of the thymines to cytosines
in this motif in the HIV-1LAI subtype B LTR (N5-Mut in
Figure 4A); in fact, these mutations convert the site to a
canonical NF-jB p50/p65 site that is found in the major
histocompatibility complex class I H2-jB enhancer and other
promoter regions (reviewed in [50]). An EMSA using the wild-
type and NFAT5 (N5-Mut) mutant oligonucleotides con-
ﬁrmed that changing the CC dinucleotide to TT in the N5-
Mut did indeed signiﬁcantly inhibit NFAT5 binding without
disrupting the binding of p50/p65. In fact, the binding of p50/
p65 when the site was converted to the major histocompat-
ibility complex class I H2-jB site was enhanced (Figure 4A).
We next were interested in determining whether this
speciﬁc mutation of the NFAT5 binding site resulted in a
change in LTR-mediated gene activation. We thus introduced
the CC to TT change in the context of an HIV-1 B subtype
(HIV-1LAI) LTR-luciferase reporter gene spanning  208 to
þ64 nt relative to the transcription start site, transfected the
wild-type and NFAT-5 mutant LTR reporter genes into the
human monocytic cell line THP-1, and measured LTR driven
luciferase activity 36 h later. We note that NFAT5 is present
in nuclear extracts from unstimulated THP-1 monocytic cells
and binds to the wild-type LTR oligonucleotide (Figure S1).
The NFAT5-speciﬁc mutation, which does not impact NF-jB
binding to this site, inhibited HIV-1LAI LTR expression by
approximately 65% (p , 0.01) (Figure 4B). These data thus
provide a direct link between the binding of NFAT5 at the
core NFAT5/NF-jB/NFATp element of the HIV-1LAI LTR and
the ability of this LTR to activate transcription.
Blocking NFAT5 by siRNA Inhibits HIV-1 Production in
HeLa-CD4 Cells
Consistent with the ﬁndings above in monocytic THP-1
cells and with our previous studies in ﬁbroblast cells [48], we
also detected constitutive levels of NFAT5 mRNA and protein
in HeLa-CD4 cells (Figure 5A and 5B). Notably, HeLa-CD4
cells can be infected with and sustain replication of HIV-1LAI
and have been successfully used in studies employing RNA
interference [46,58]. These cells thus allowed us to determine
whether NFAT5 played a functional role in HIV-1 replication
using RNA interference. We designed small interfering RNA
(siRNA) directed against NFAT5 and used these to block
Figure 4. Specific Disruption of NFAT5 Binding Impairs LTR–Reporter
Gene Activity in Monocytic THP-1 Cells
(A) Disruption of NFAT5 binding does not impair NF-jb (p50/p65)
binding. An EMSA is shown using recombinant NFAT5 and NF-jB
proteins with an oligonucleotide matching the NFAT5/NF-jb site from
the HIV-1LAI (wild-type [WT]) or an oligonucleotide with a mutation in the
nt predicted to be required for NFAT5 binding (N5-Mut), but not NF-jB
binding (shown at the bottom of the figure).
(B) Mutation of the NFAT5 binding site significantly reduces HIV-1LAI LTR
reporter activity in THP-1 cells. HIV-1LAI LTR-Luc reporter constructs that
contained  208 to þ64 nt relative to the transcriptional initiation site of
HIV-1LAI, and that were isogenic except for the specific N5 mutation,
were transfected into THP-1 cells with the Renilla luciferase (pRL-TK)
control plasmid. Luciferase activity was determined 26 h later. The LTR
mutation, which abolishes NFAT5 binding to the promoter/enhancer
region, significantly (**, p , 0.01) suppressed LTR-dependent activity of
transcription compared with WT in THP-1 cells.
doi:10.1371/journal.ppat.0020130.g004
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NFAT5: An HIV-1 Host Factor in MonocytesNFAT5 mRNA expression (Figure 5A) and protein produc-
tion (Figure 5B) in HeLa-CD4 cells. To conﬁrm the speciﬁcity
of NFAT5 RNA inhibition, we designed another distinct
NFAT5-speciﬁc siRNA targeting a different exon of NFAT5.
We performed four independent experiments and demon-
strated that both siRNAs signiﬁcantly inhibited (p , 0.01)
NFAT5 mRNA expression in HeLa-CD4 cells (Figure 5A). We
also investigated the impact of siRNA directed against NFAT5
upon NFAT5 protein production using intracellular staining
for NFAT5. As shown in the experiment displayed in Figure
5B (which is representative of four independent experi-
ments), NFAT5 protein expression was lower in the cells
transfected with an NFAT5 siRNA than in those mock
transfected or transfected with the GFP siRNA.
We next transfected HeLa-CD4 cells with each of the two
NFAT5-speciﬁc siRNAs or with GFP siRNA as a control. The
cells were then infected with HIV-1LAI. At day 3 post-
infection, we performed internal staining with HIV-1 p24-
RD1 conjugated antibody and analyzed the cells by ﬂow
cytometry (Figure 5C). No reduction in intracellular virus
level was observed when the cells were transfected with GFP
siRNA as compared with mock-transfected cells. However,
there were 33.3% and 36.27% reductions in intracellular p24
levels in cells transfected with these speciﬁc NFAT5 siRNAs
relative to mock-transfected cells and cells transfected with
GFP siRNA (Figure 5C). Furthermore, using a p24 ELISA
assay, we demonstrated that virus replication was signiﬁcantly
(p , 0.04) reduced in the supernatants of cells transfected
with either one of the speciﬁc NFAT5 siRNAs compared with
virus replication in supernatants from cells that were trans-
fected with GFP siRNA or mock transfected (Figure 5D).
NFAT5 Is Expressed in Primary Macrophages and Plays an
Important Role in the Replication of HIV-1 Subtypes B, C,
and E in MDMs
Given that macrophages are a major virus reservoir as
infection progresses, we next determined whether NFAT5 is
produced in terminally differentiated primary macrophages
Figure 5. NFAT5 Plays an Important Functional Role in HIV-1 Replication in HeLa-CD4 Cells
(A) Real-time PCR showing that HeLa-CD4 cells constitutively express NFAT5 mRNA. Using siRNA-targeting NFAT5, we were able to reduce NFAT5 mRNA
levels significantly (p , 0.01) compared with that of GFP siRNA or mock-transfected cells. To confirm that NFAT5 knockdown was specific, we used two
NFAT5 siRNAs (NFAT5#1 and NFAT#2) targeting two different exons of the NFAT5 gene. We chose the sequence siRNA to GFP because this sequence
has been validated and shown to have no nonspecific effects upon HIV replication [46,58]. Results show the average of four independent experiments.
(B) Flow cytomety analysis of intracellular NFAT5 levels in HeLa-CD4 cells. A representative experiment of a flow cytometry analysis using a monoclonal
antibody to NFAT5 demonstrated that intracellular NFAT5 protein levels were lower in the cells transfected with NFAT5 siRNA than those that were
transfected with GFP siRNA or mock transfected. The experiment is representative of four independent experiments.
(C) Flow cytometry analysis of intracellular p24 levels in HIV-1LAI infected HeLa-CD4 cells. Intracellular HIV-1 levels were determined using a p24-RD1
conjugate in a representative experiment. Three days following virus infection, intracellular p24 was lower in cells transfected with NFAT5 siRNA
targeting two different exons of NFAT5 (NFAT5#1 and NFAT5#2; 33.3% and 36.27% inhibition, respectively) than in cells transfected with a GFP control
siRNA or mock transfected. This experiment is representative of four independent experiments.
(D) Cell-free p24 production in supernatants of HIV-1LAI infected HeLa-CD4 cells. HIV-1 replication as assessed by p24 ELISA is significantly (p , 0.04)
lower in cellular cultures transfected with NFAT5 siRNA targeting two different exons of NFAT5 (NFAT5#1 and NFAT5#2) than in cells mock transfected
or transfected with the GFP control siRNA.
doi:10.1371/journal.ppat.0020130.g005
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NFAT5: An HIV-1 Host Factor in Monocytesand whether it plays a role in virus replication. We generated
MDMs from normal donor peripheral blood mononuclear
cells and found that NFAT5 mRNA (Figure 6A) and protein
(Figure 6B) are constitutively expressed in these cells.
We performed ﬁve independent experiments and demon-
strated that NFAT5 siRNA (NFAT5#1) signiﬁcantly inhibited
(p , 0.02) NFAT5 mRNA expression in MDM cells (Figure
6A). We note that the second speciﬁc NFAT5 siRNA behaved
identically in two experiments where it was tested (unpub-
lished data). We also investigated the impact of siRNA
directed against NFAT5 upon NFAT5 protein production
using intracellular staining for NFAT5. As shown in the
experiment displayed in Figure 6B, (which is representative of
ﬁve independent experiments), NFAT5 protein expression
was lower in the cells transfected with an NFAT5 siRNA than
in those mock transfected or transfected with GFP siRNA.
We next transfected MDMs with NFAT5 siRNA or GFP
siRNA (control) and then 4 d later infected the cells with HIV-
1Bal (B subtype) and monitored virus replication. At day 4
post-infection, we performed intracellular staining with HIV-
1 p24-RD1 conjugated antibody and analyzed the cells by ﬂow
cytometry. As shown in Figure 6C, there was a 26.9%
reduction in intracellular p24 levels in cells transfected with
NFAT5 siRNA compared with the cells transfected with GFP
siRNA–transfected cells.
MDMs also provided us the opportunity to test the effect of
NFAT5 inhibition upon the replication of the M-tropic HIV-
1 subtype C and E primary isolates. We therefore transfected
Figure 6. MDMs Constitutively Express NFAT5, Which Is Required for Replication of HIV-1 Representative Isolates from Subtypes B, C, and E
(A) NFAT5 expression was detected in human MDMs using real-time PCR. NFAT5 mRNA expression was significantly inhibited 6 d after transfection with
NFAT5 siRNA (NFAT5#1) compared with cells transfected with GFP siRNA or mock transfected (p , 0.02).
(B) Flow cytomety analysis of intracellular NFAT5 levels in MDMs. A representative experiment is shown of a flow cytometry analysis of MDM using a
monoclonal antibody to NFAT5. Intracellular NFAT5 protein levels were lower in the cells transfected with NFAT5 siRNA than in those transfected with
GFP siRNA or those mock transfected. The experiment is representative of five independent experiments.
(C) Flow cytometry analysis of intracellular p24 levels in HIV-1BAL–infected MDMs. Mock- or siRNA-transfected MDMs were infected with HIV-1Bal, and
intracellular p24 levels were determined on day 4 post-infection with flow cytometry using the p24-RD1 conjugated antibody. Intracellular virus levels
were 26.9% lower in the cells transfected with NFAT5 siRNA than in GFP siRNA–transfected cells.
(D) Knockdown of NFAT5 RNA inhibits replication of HIV-1 representative isolates from subtypes B, C, and E. Cell-free virus replication was determined
by p24 ELISA at day 3, 6, 9, and 13 post-infection of MDMs by subtype B (HIV-1BAL), C (HIV-198IN22), or E (HIV-193TH64) viruses as indicated. Free virus levels
were lower in the cells transfected with NFAT5 siRNA compared with the cells transfected with GFP siRNA (control) in cellular supernatants at all the
time points monitored and indicated in the figure. Notably, on day 13 post-infection, inhibition of free virus levels in the NFAT5 siRNA–transfected
cultures was on average 1.9-fold lower for HIV-1BAL, 2-fold lower for HIV-198IN22, and 2.1-fold lower for HIV-193TH64 compared with GFP siRNA–
transfected cultures.
doi:10.1371/journal.ppat.0020130.g006
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NFAT5: An HIV-1 Host Factor in MonocytesMDMs with NFAT5 siRNA or GFP siRNA (control) and then 4
d later infected the cells with HIV-198IN22 (C subtype), HIV-
193TH64 (E subtype), or HIV-1Bal (B subtype) and performed a
p24 ELISA to determine free virus levels in MDM cultures
infected with the three viruses in the presence or absence of
NFAT5 siRNA over time. The p24 levels from MDMs infected
with the representative B, C, and E isolates were inhibited in
the cultures transfected with NFAT5 siRNA compared with
the control cultures transfected with GFP siRNA or mock
transfected over the period of time monitored (Figure 6D).
On day 13 post-infection, we analyzed the inhibition caused
by NFAT5 siRNA versus transfection with the GFP siRNA or
mock transfection. We observed that for the subtype B, C,
and E isolates, speciﬁc inhibition by knocking down NFAT5
was on average 1.9-, 2-, and 2.1-fold, respectively, at this time
point (Figure 6D). We obtained similar results using each of
the two speciﬁc siRNAs targeting two different exons of
NFAT5 in all of the experiments in MDMs (unpublished
data).
To verify that infection by HIV-1 itself was not causing an
increase in NFAT5 mRNA levels, we infected MDMs with live
or heat-inactivated HIV-198IN22, HIV-193TH64, or HIV-1Bal and
measured NFAT5 levels by real-time PCR at 24 and 48 h after
infection. There was no change in NFAT5 levels at either time
point after infection of cells with live virus or incubation with
heat inactivated viruses as compared with uninfected cells
(unpublished data). Taken together, these results demonstrate
that NFAT5 plays a signiﬁcant role in the replication of HIV-
1 from subtype B, C, and E isolates in primary differentiated
macrophages.
Discussion
In this study, we have combined in vitro and ex vivo studies
with sequence analysis approaches to reveal a new function
for NFAT5 in the replication of major subtypes of HIV-1 in
cells of the monocyte/macrophage lineage. Previous studies
have demonstrated that a range of transcription factors can
interact with the LTR of HIV-1 subtype B (reviewed in [12]),
and it has been proposed that distinct sets of host factors may
direct transcription driven by the HIV-1 LTR in T cells and
macrophages [7]. Remarkably, the functional NFAT5 site, 59-
GGGACTTTCCA-39, that we have identiﬁed in the LTR of
isolates of HIV-1 subtypes B, C, and E, is conserved not only
across HIV-1 Group M subtypes A through G, but also in
HIV-1 Group O and HIV-2 isolates, as well as SIV isolates
from multiple primate species (Figure 3).
The evolutionary pressure toward conservation of this
NFAT5 site is particularly striking given the variability of
LTR sequences between subtypes and HIV species [17,56],
including the number and arrangement of transcription
factor binding sites, as illustrated by the binding of NF-jB
proteins to HIV-1 subtype B, C, and E LTRs in this study
(Figure 2A). Furthermore, we have shown that a single
nucleotide difference, a 39 adenine, between the NFAT5 site
and an upstream NF-jB binding site, confers selective
binding of NFAT5 to this conserved enhancer element
(Figure 2).
NFAT5 is unique among the NFAT proteins both in its
DNA-binding properties and in the upstream signal trans-
duction pathways that regulate its activity. Unlike the other
NFAT family members, NFAT5 binds as an obligate dimer and
does not act coordinately with Fos and Jun proteins. While the
nuclear translocation of other NFAT proteins is tightly
regulated by the calcium-dependent phosphatase calcinuerin,
the activity of NFAT5 has been shown to be regulated by
osmotic stress and integrin activation [41–43]. Our ﬁndings
that NFAT5 is involved in HIV-1 replication in cells of the
monocyte/macrophage lineage, as well as in a nonlymphoid
model cell line, and that its functional DNA binding site is
highly conserved, provide an initial insight into other
potential upstream regulatory mechanisms that further
distinguish the physiologicalr o l eo ft h i se v o l u t i o n a r i l y
divergent NFAT protein from its calcineurin-responsive
counterparts. It is interesting to note that the HIV-1 LTR
can be activated by osmotic stress in HeLa cells [59]; thus, the
upstream signaling pathways involved in NFAT5-dependent
HIV-1 replication may overlap with those responsible for
osmotic stress-induced transcription of NFAT5-dependent
cellulargenes.Thefeaturesofthesesignaling pathwaysremain
to be determined [34]. Working backward from this functional
binding site may thus reveal critical, evolutionarily conserved
mechanisms through which constitutive or activated signals
are propagated from the cell membrane, resulting in NFAT5-
dependentgeneexpressionthatiscriticalinmaintainingHIV-
1 replication in the monocyte/macrophage lineage.
Even though both NF-jB and NFAT proteins interact with
the conserved NFAT5 site, our results have demonstrated a
speciﬁc role for NFAT5 in the replication of HIV-1 in cells of
the monocyte/macrophage lineage. We have established that
NFAT5 mRNA and protein are constitutively present in
primary human macrophages. Strikingly, replacement of the
NFAT5 site with a canonical NF-jB site inhibits activity of the
HIV-1 LTR, and direct inhibition of NFAT5 using siRNA
inhibits replication of HIV-1 subtypes B, C, and E in primary
human macrophages. By examining multiple HIV-1 subtypes,
we have discovered a function for a binding site conserved
across viral types and even across primate species; this
ﬁnding, together with the importance of macrophages as a
viral reservoir through which HIV-1 can persistently infect
multiple tissues, underscores the potential of the NFAT5–
LTR interaction as a therapeutic target to suppress virus
replication and disease progression.
Supporting Information
Figure S1. NFAT5 Binds to the LTR in THP-1 Cells
An EMSA with nuclear extracts from unstimulated THP-1 monocytic
cells and the wild-type LTR oligonucleotide is shown. Reactions were
untreated (-) or incubated with a speciﬁc anti-NFAT5 antibody (anti-
NFAT5) or a control antibody (anti-Ig control). Note that the
NFAT5–DNA complex (indicated by the arrow) is ablated by the
anti-NFAT5 antibody.
Found at doi:10.1371/journal.ppat.0020130.sg001 (1.0 MB TIF).
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